Related Experiment Video
Updated: Jul 25, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Association of Elevated Glycated Hemoglobin (HbA1c) in COVID-19 Patients Admitted to the Intensive Care Unit and
Adan M Cuevas Velazquez1, Wern Lynn Ng1, Evelyn J Calderon Martinez1
1Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, USA.
Insights
Elevated glycated hemoglobin (HbA1c) levels in COVID-19 patients did not correlate with increased in-hospital mortality. However, higher HbA1c was linked to a greater need for insulin drip in ICU patients.
Area of Science:
- Critical Care Medicine
- Endocrinology
- Infectious Diseases
Background:
- Diabetes is a significant comorbidity in COVID-19 patients.
- Glycemic control, indicated by HbA1c, may influence COVID-19 outcomes.
- Understanding this association is crucial for managing diabetic patients with COVID-19.
Purpose of the Study:
- To investigate the association between elevated glycated hemoglobin (HbA1c) levels and clinical outcomes in COVID-19 patients admitted to the ICU.
- To assess the relationship between HbA1c levels and in-hospital mortality, 90-day mortality, insulin drip requirement, and length of stay.
Main Methods:
- Observational retrospective study using electronic health records from UPMC Central PA Hospitals.
- Analysis of 384 diabetic COVID-19 patients admitted to the ICU between May 2021 and May 2022.
- Stratification of patients based on HbA1c levels ( <7%, 7-9%, >9%) obtained within three months prior to admission.
Main Results:
- Mortality rates were 54.1% (HbA1c<7%), 65.49% (HbA1c 7-9%), and 43.18% (HbA1c>9%).
- No linear association was found between higher HbA1c and increased in-hospital mortality.
- 90-day mortality rates did not significantly differ across HbA1c groups, but insulin drip need increased with higher HbA1c.
Conclusions:
- Higher HbA1c levels in diabetic COVID-19 ICU patients were not associated with increased in-hospital or 90-day mortality.
- Increased need for insulin drip was observed in patients with higher HbA1c levels.
- BMI did not show significant differences across HbA1c groups, with most patients classified as low-risk.
Abstract:
Aim The study aimed to collect retrospective data to investigate the association between elevated glycated hemoglobin (HbA1c) levels and clinical outcomes in COVID-19 patients admitted to the ICU, including in-hospital mortality and 90-day mortality. Methods This is an observational retrospective study using electronic health records of patients with diabetes admitted to the ICU with COVID-19 across the University of Pittsburgh Medical Center (UPMC) in Central PA Hospitals. Our retrospective analysis was performed on patients admitted to the ICU between May 1st, 2021, to May 1st, 2022. The HbA1c level obtained within three months before their admission was evaluated and stratified to show their association with clinical outcomes, including in-hospital mortality and 90-day mortality. Additionally, the need for insulin drip and ICU and hospital length of stay were compared among these patients. Results We analyzed 384 patients, which were distributed in three groups. The majority of the patients (183 patients or 47.66%) had an HbA1c below 7%, 113 patients (29.43%) had an HbA1c between 7-9%, and 88 patients (22.92%) had an HbA1c above 9%. The group with an HbA1c<7% had a mortality rate of 54.1% during the hospital stay, with a median stay of 13 days. The patients with an HbA1c between 7-9% had a higher mortality rate of 65.49% with a median stay of 12 days. The patients with HbA1c>9% had a mortality rate of 43.18% with a median stay of 11.5 days. Conclusion This retrospective study found that there was no linear association between higher HbA1c levels and a higher risk of mortality during hospitalization. The 90-day mortality rate was not statistically different among the three HbA1c groups. The need for insulin drip was higher in patients with higher HbA1c levels. The majority of patients in all three groups were classified as low-risk based on their BMI, and there were no significant differences in the distribution of patients across BMI categories in the HbA1c groups.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
06:46A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Related Concept Videos
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes: Symptoms, Diagnosis, and Complications
Hypoglycemia and Glucagon
Diabetes Mellitus: Type 2 and Gestational
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Acute Pancreatitis II: Clinical Manifestations and Management